Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -91.36% is 45% below its 5-year average of -63.03%, near the high end of its 5-year range (-10245.45%–0.00%).
103.27% below its 12-month average of -44.94%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): -5.34%.
OPERATING MARGIN
-91.36%
OPERATING MARGIN AVG TTM
-44.94%
OPERATING MARGIN AVG 3Y
-199.08%
OPERATING MARGIN AVG 5Y
-63.03%
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-103.27%
CURRENT VS 3Y AVG
+54.11%
CURRENT VS 5Y AVG
-44.95%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Phathom Pharmaceuticals, Inc.
Market Cap
$548.51M
Operating Margin
-91.36%
TTM Avg
-44.94%
3Y Avg
-199.08%
5Y Avg
-63.03%
Market Cap
$557.32M
Operating Margin
-29.35%
TTM Avg
-5.63%
3Y Avg
-52.07%
5Y Avg
-106.16%
Market Cap
$538.01M
Operating Margin
-18477.83%
TTM Avg
-130078.39%
3Y Avg
-65039.20%
5Y Avg
-43359.46%
Market Cap
$533.04M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$531.98M
Operating Margin
-1.90%
TTM Avg
-16.29%
3Y Avg
-781.66%
5Y Avg
-851.82%
Market Cap
$531.52M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$529.58M
Operating Margin
-5150.80%
TTM Avg
-3279.53%
3Y Avg
-6989.17%
5Y Avg
-4746.54%
Market Cap
$571.13M
Operating Margin
46.95%
TTM Avg
-1.63%
3Y Avg
-11705.79%
5Y Avg
-12269.85%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. (PHAT) | $548.51M | -91.36% | -44.94% | -199.08% | -63.03% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $557.32M | -29.35% | -5.63% | -52.07% | -106.16% |
| ProKidney Corp. (PROK)vs › | $538.01M | -18477.83% | -130078.39% | -65039.20% | -43359.46% |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $533.04M | 0.00% | 0.00% | 0.00% | 0.00% |
| Delcath Systems, Inc. (DCTH)vs › | $531.98M | -1.90% | -16.29% | -781.66% | -851.82% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $531.52M | 0.00% | 0.00% | 0.00% | 0.00% |
| Shattuck Labs, Inc. (STTK)vs › | $529.58M | -5150.80% | -3279.53% | -6989.17% | -4746.54% |
| CorMedix Inc. (CRMD)vs › | $571.13M | 46.95% | -1.63% | -11705.79% | -12269.85% |
| Immix Biopharma, Inc. (IMMX)vs › | $524.43M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
82.9%
Operating Margin
-91.4%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | -5.34% |
| 2026-03-31 | -26.55% |
| 2025-12-31 | -10.29% |
| 2025-09-30 | -30.85% |
| 2025-06-30 | -151.69% |
| 2025-03-31 | -276.53% |
| 2024-12-31 | -200.30% |
| 2024-09-30 | -432.95% |
| 2024-06-30 | -1055.43% |
| 2024-03-31 | -3658.68% |
| 2023-12-31 | -10245.45% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
